

COMMERCIAL INTEREST AT ESMO ANNUAL MEETING 2018



10/12/2018

Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool

With this analytical tool BioSeeker reveals the direction of commercial drug development emerging from the European Society of Medical Oncology (ESMO 2018) congress, featuring more than 2000 abstracts of the latest ground-breaking science/clinical development in oncology. This tool will tell you anything from what immunotherapies are dominating at ESMO to the development of novel targets, never previously pursued in oncology.

"Needful insights for people following the progress in Cancer R&D"

Medical & Scientific Advisor,
French pharma company

"1st Oncology is the leading intelligence service in oncology which is most up-to-date and granularized compared to 12 other sources I recently evaluated"

Manager, Scientific Library,
Big Pharma

Center stage for the "Commercial Interest at ESMO Annual Meeting 2018" is to feature where ESMO makes a footprint in the commercial cancer drug development landscape. What's so compelling with this tool is that is constructed from an exceedingly solid knowledgebase of more than 12,500 drugs, 4,000 companies/organizations and tens of thousands of interventional clinical trials in oncology.

The hotbed of ESMO 2018 is energized from an underlying cluster of roughly 300 drugs ranging from preclinical to marketed in maturity. Two fifths (40%) of these are immune-oncology drugs including Immune checkpoint drugs, Cancer vaccines, Bispecific immunomodulators, CAR/TCR therapies and Oncolytic virotherapies. In the spotlight of this year's Nobel Prize in Physiology or Medicine ESMO 2018 features nearly 40 different immune checkpoint drugs, by far the most reported on immunotherapy at ESMO and even more so if we take into account all combination therapy reports with the same. Other hot progress areas in cancer therapeutics at ESMO include DNA Damage Response (DDR) drugs, epigenetic therapies, protein kinase inhibitors and antibody-drug conjugates (ADCs).

The number of targets related to the aforementioned drugs at ESMO 2018 is close to 200 were the top five drug targets are: KDR (17), EGFR (15), HER2 (14), KIT (13) and FLT4 (11). On the contrasting end of these we find fourteen unique targets belonging to first-in-class drugs like Astellas' enfortumab vedotin, a fully humanized monoclonal antibody that delivers the microtubule-disrupting agent monomethyl auristatin E to tumors expressing

Nectin-4, which is highly expressed in 97% of metastatic urothelial cancer patient samples.

There is a global presence of companies at ESMO 2018 ranging from big pharma to startups like Arcus Biosciences (USA), CStone Pharmaceuticals (China), Neon Therapeutics (USA), NEOMED Therapeutics 1 (Canada) and Oblique Therapeutics (Sweden). It is noteworthy to mention that both Arcus Biosciences and Neon Therapeutics are 2016 winners of the prestigious Fierce 15 Biotech award. This prestigious award has come to symbolize novelty and being at the forefront of biotechnology development among businesses. The winners of this award are aiming at breakthroughs and big things, not at being 'me-too'. For an example Arcus Biosciences is at ESMO reporting stellar safety data from its phase 1 study of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors. And this is only the tip of the iceberg of clinical trial results presented at ESMO. The "Commercial Interest at ESMO Annual Meeting 2018" identifies several hundred key clinical trials and makes them easily discoverable with both primary and secondary endpoint results.

The ESMO congress is Europe's largest clinical oncology meeting which is a great event that tells us the direction of commercial drug development in oncology. This tool is a must have for anyone with an interest in oncology who wants to save time and effort and more successfully analyze the direction emerging from this meeting.

Commercial Interest at ESMO Annual Meeting 2018

ANALYTICAL TOOL

POWER-UP YOUR COVERAGE OF ESMO & FIND OUT WHAT THE COMPETITION IS UP TO

The Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool significantly shortcuts your work-load to analyze the ESMO meeting by allowing you to skip the hassle of identifying new technologies, drugs, targets, start-ups etc. We've already done that for you! Hence you are able to cut straight to the valuable analysis from the meeting and in seconds find out what the competition is doing and what is being introduced to the world for the first time!

ANALYZING THE COMPETITIVE POSITIONS OF REVEALED DRUGS

The more than 270 drugs identified in this tool are analyzed according to "hot" areas in oncology where cancer drug development is being focused today, including areas such as exciting Startups, Immune checkpoint drugs, Epigenetic therapies, DNA Damage response drugs and much more. With a simple point and click interface you can navigate any hot area, drill down into sub-specific areas such as ongoing combination trials, biomarker analysis, selected scientific

abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

GET FOCUS AND UNBIASED INSIGHTS EVEN AFTER ESMO

To further illuminate the reader, this tool also includes the latest development for the entire ESMO pipeline, detailing both positive and negative pipeline development throughout the lifetime of your access. This provides comprehensive insights to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more.

HIGHER PRODUCTIVITY FORMAT AND A TOOL YOU CAN GROW WITH

Unlike a static report which just represents a particular snapshot in time, this Analytical Tool comes with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

WHY BUY THIS TOOL?

The ESMO congress is Europe's largest clinical oncology meeting which is a great event that tells us the direction of commercial drug development in oncology. This tool is a must have for anyone with an interest in oncology who wants to save time and effort and more successfully analyze the direction emerging from this meeting.

SUPPORT AND INSPIRATION AT YOUR FINGER-TIPS

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

FORMAT, FREE UPDATES & PRICING

This is 12 months of access to an ever-green Analytical Tool that you access simply online. It is continuously updated with new information and analysis throughout your 12 month access period, ensuring that you stay up to date with any development surrounding these drugs at ESMO. At the end of your access period, if you so wish, you can choose to renew access to the next year ESMO as well.

Single user: \$1,450 USD

Enterprise-wide: \$4,350 USD

SYSTEM REQUIREMENTS

- Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
- Internet access

CONTENTS ENTRIES OF THE COMMERCIAL INTEREST AT ESMO ANNUAL MEETING 2018: ANALYTICAL TOOL

1 Commercial Interest at ESMO Annual Meeting 2018: An Overview

1.1 Current Developmental Stage & Status of Drugs at ESMO 2018

1.2 Timeline Development Review of Drugs at ESMO 2018

1.3 Compound Types of Drugs Present at ESMO 2018

1.4 Disease Target Analysis of Drugs at ESMO 2018

1.4.1 Target Profiles

1.5 Pursued Tumor Types

1.6 Recent Clinical Trial Results from Drugs at ESMO 2018

1.7 Clinical Biomarkers in Play among Drugs at ESMO 2018

1.8 Combination Therapies of Drugs at ESMO 2018

1.9 Drugs at ESMO 2018 with Orphan Drug Designation

1.10 Previous Advancement Reports of Drugs at ESMO 2018 Through the Lenses of Seven Other Major/Influential Cancer Meetings: Selected Abstracts

1.10.1 AACR

1.10.2 AACR–NCI–EORTC

1.10.3 ASCO

1.10.4 ASGCT

1.10.5 ASH

1.10.6 EHA

1.10.7 SITC

1.11 Stakeholders of Drugs at ESMO 2018: Part I Originators/Owners

1.12 Stakeholders of Drugs at ESMO 2018: Part II Licensors/Collaborators

1.13 Business Development & Licensing Contacts

1.14 Drug Profiles

2 Startups at ESMO 2018

3 Bispecific Drugs at ESMO 2018

4 Deals & Alliances Among Drugs at ESMO 2018

5. Orphan Drugs at ESMO 2018

6. Breakthrough Therapies at ESMO 2018

7. Cancer Vaccines at ESMO 2018
8. CAR/TCR Therapies at ESMO 2018
9. Oncolytic Virotherapies at ESMO 2018
10. Immune Checkpoint Drugs at ESMO 2018
11. Epigenetic Therapies at ESMO 2018
12. DNA Damage Response Drugs at ESMO 2018
13. Protein Kinase Inhibitors at ESMO 2018
14. Antibodies at ESMO 2018
15. Peptides at ESMO 2018
16. Nucleic Acid Therapies at ESMO 2018
17. Conjugated/Fusion Drugs at ESMO 2018
- 18 Pipeline Review & Analysis of Drugs at ESMO 2018by Highest Stage:
 - 18.1 Marketed
 - 18.2 Phase III
 - 18.3 Phase II

18.4 Phase I

18.5 Preclinical

18.6 Discovery

18.7 Patent

19 Pipeline Review & Analysis of Drugs at ESMO 2018 by 228 Tumor Indications, of which the 5 largest are:

19.1 Solid Tumors

19.2 Non-small Cell Lung Cancer

19.3 Breast Cancer

19.4 Colorectal Cancer

19.5 Ovarian Cancer

19.6 ... 19.228

SAMPLE VIEWS

Here follows six sample views from our Analytical Tool series, exemplifying some of the breakdowns you will find in your Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool. Every part of the Analytical Tool is continuously updated twice a week, making it just as fresh and informative today as it will be in a year from now!

Introduction to Examples

1. Breakdown & Analysis of Deep Pipeline Information by Main Chapters
2. Access to Progress Report on Individual Drugs Through In-depth and Continuously Updated Drug Profiles. These can be exported into Excel and CSV Files. The Same Goes for Target Profiles and Company Profiles containing Business Development & Licensing Contacts etc.
3. Target Review & Analysis by Main Chapters and Access to In-depth Target Profiles
4. Continuous Review & Analysis of Clinical Results by Main Chapters and Access to Conference Abstracts and Abstracts of Publications
5. Combination Therapy Analysis of Clinical Trials
6. Enhanced Company Profiles for Head-to-Head Pipeline Comparison and Analysis & More

Breakdown & Analysis of Deep Pipeline Information by Main Chapters

Chapters

↻ Getting Started!
↻ Full Overview
↻ Startups
↻ Orphan Drugs

↻ Breakthrough Therapies
↻ Cancer Vaccines
↻ CAR/TCR Therapies
↻ Oncolytic Virotherapies

↻ Immune Checkpoint Drugs
↻ Epigenetic Therapies
↻ DNA Damage Response
↻ Protein Kinase Inhibitors

↻ Antibodies
↻ Peptides
↻ Nucleic Acid Therapies
↻ Conjugated/Fusion Drugs
↻ Bispecific Drugs

Highest Stage Chapters ▼

Indication Chapters ▼

Chapter
Chapter

Quick Reports

Select Drug ▼

Select Target ▼

Select Organization ▼

Report
Report
Report

Chapter: Cancer Drugs at ESMO (2018)

Analyze By:

- [↻ Drug Status](#)
- [↻ Pipeline Stages](#)
- [↻ Development Timeline](#)
- [↻ Compound Types](#)
- [↻ Targets](#)

196 Targets

Data	Chart
<p style="font-size: small;">Redraw table for full export</p> <p>Show 10 entries</p> <p style="font-size: small;">Export Table Data:</p> <div style="display: flex; gap: 5px;"> 📄 📄 📄 📄 </div> <p style="font-size: small;">Search:</p>	<p style="font-size: small;">Toggle Legend</p> <p style="text-align: center; font-weight: bold;">Targets</p> <div style="display: flex; justify-content: space-around; align-items: center;"> XPO1 TNFRSF4 N/A KDR </div> <p style="text-align: right; font-size: small;">Export</p>

Access to Progress Report on Individual Drugs Through In-depth and Continuously Updated Drug Profiles. The Same Goes for Target Profiles and Company Profiles containing Business Development & Licensing Contacts etc.

1stOncology - TARGETING THE CD47-SIRPα AXIS IN ONCOLOGY

Sub-Chapters:

- 🔍 Drug Status
- 🔍 Pipeline Stages
- 🔍 Development Timeline
- 🔍 Compound Types
- 🔍 Targets
- 🔍 Pursued Tumor Types
- 🔍 Clinical Results
- 🔍 Clinical Biomarkers
- 🔍 Combination Therapy
- 🔍 Immuno-Oncology Pipeline
- 🔍 Orphan and Breakthrough Drugs
- 🔍 Selected Abstracts
- 🔍 Originators/Owners
- 🔍 Licensors/Collaborators
- 🔍 BD&L Contacts
- 🔍 Drug Profiles

Drug Profiles, Companies and Targets

Show 10 entries

Name	Company	Country	Target	Target	Target	Target	Target
1F8-GMCSF	I-Mab Biopharma	China					
2nd gen. CD47 antibodies	Arch Oncology	USA					
ABP-500	Abpro Therapeutics	USA	Antibodies	CD47 TNFRSF12A	Highest Stage: Discovery	Number of Developmental Projects: 01	Active
ALX148	ALX Oncology	USA	Proteins	CD47	Highest Stage: Phase I		Active

1stOncology - Detailed Drug Report

Hu5F9-G4 (Forty Seven)

[Full Drug Report](#)
[Latest Social Intelligence](#)
[Selected Abstracts](#)
[BD&L Contacts](#)

Drug Name	Hu5F9-G4
Drug Status	Active
Drug Synonyms	5F9 anti-CD47 mAb
Search this Drug with	PubMed Google
Company	Forty Seven (USA)
Partners	MD Anderson Merck KGaA Stanford University

Description

Hu5F9-G4 is a humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47 which is under development by Stanford Cancer Institute (Stanford University) for the treatment of acute myeloid leukemia (Cancer.gov, OCT 10, 2014, [View Source](#)).

Highlights

Positive

2018 MAY 3
On May 3, 2018 Forty Seven reported that the U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to 5F9 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (Press release, Forty Seven, MAY 3, 2018, [View Source](#) [SID1234527526]).

Total of 1 Additional Positive Highlights. [Show/Hide](#)

Target Review & Analysis by Main Chapters and Access to In-depth Target Profiles

Sub-Chapters:

- [↻ Drug Status](#)
- [↻ Pipeline Stages](#)
- [↻ Development Timeline](#)
- [↻ Compound Types](#)
- [↻ Targets](#)
- [↻ Pursued Tumor Types](#)
- [↻ Clinical Results](#)
- [↻ Clinical Biomarkers](#)
- [↻ Combination Therapy](#)
- [↻ Immuno-Oncology Pipeline](#)
- [↻ Orphan and Breakthrough Drugs](#)
- [↻ Selected Abstracts](#)
- [↻ Originators/Owners](#)
- [↻ Licensors/Collaborators](#)
- [↻ BD&L Contacts](#)
- [↻ Drug Profiles](#)

15 Targets

Data

Redraw table for full export

Show entries

Export Table Data:

[📄](#) [📄](#) [📄](#) [📄](#)

Chart

[Toggle Legend](#)

Targets [Export](#)

TNFSF9

CD47

1stOncology - Drug Target Atlas in Oncology - Online

Target Report: CD47 - (CD47 molecule)

Target: CD47

Mutations: SIRPA

Pathways: CD274

Tumor Expression: VEGFA

Interactions: CD19

Approaches: CD247

Clinical Biomarkers

Compounds: CD40

Drugs: CSF2RA

Indications: ERBB2

Companies:

Clinical Biomarkers

Listed by Clinical Trial | Clinical Results from Trials with Biomarkers

Show entries

Clinical Trial	Drugs	Biomarkers	Developmental Stage	Indications
NCT02953782	Hu5F9-G4 [Forty Seven] - Phase II	FISH (DNA) (Technique) KRAS - Mutant - Expression/Level (Protein) KRAS - Wild-type (Protein) PET (Tissue) (Technique)	Phase II Clinical Trial	Cancer
NCT02367196 (Results Available)	CC-90002 [Celgene] - Phase I	All - Expression/Level (Serum) CD20 - Positive (Protein)	Phase I Clinical Trial	Cancer





Continuous Review & Analysis of Clinical Results by Main Chapters and Access to Conference Abstracts and Abstracts of Publications

Sub-Chapters:

- [Drug Status](#)
- [Pipeline Stages](#)
- [Development Timeline](#)
- [Compound Types](#)
- [Targets](#)
- [Pursued Tumor Types](#)
- [Clinical Results](#)
- [Clinical Biomarkers](#)
- [Combination Therapy](#)
- [Immuno-Oncology Pipeline](#)
- [Orphan and Breakthrough Drugs](#)
- [Selected Abstracts](#)
- [Originators/Owners](#)
- [Licensors/Collaborators](#)
- [BD&L Contacts](#)
- [Drug Profiles](#)

Clinical Results

Show entries

Export Table Data:    

Title and Key Reportings

[INITIAL PHASE 1 RESULTS OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS](#)

Key Reportings: Adverse events; Dose-Limiting Toxicities; Dosing; Maximum tolerated dose; Objective response rate; Patients; Pharmacodynamics; Preclinical; Recommended Phase II Dose

[INITIAL PHASE 1 RESULTS OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS](#)

Key Reportings: Adverse events; Dose-Limiting Toxicities; Dosing; Maximum tolerated dose; Objective response rate; Patients; Pharmacodynamics; Preclinical; Recommended

1stOncology.com: Oncology Drug Development Analysis and Surveil... — □ ×

www.1stoncology.com/drug-pipeline-update/clinicalresults.php?id=123529...

1stOncology™ - Drug Target Atlas in Oncology ☰

INITIAL PHASE 1 RESULTS OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS

Published Date: 2018-06-14
Source: European Hematology Association 2018, Abstract PF232
Related Clinical Study: [NCT02678338](#)

Key Reportings: Adverse events; Dose-Limiting Toxicities; Dosing; Maximum tolerated dose; Objective response rate; Patients; Pharmacodynamics; Preclinical; Recommended Phase II Dose

Summary: Novel and well tolerated therapies are needed in relapsed/refractory (*r/r*) acute myeloid leukemia (AML). Hu5F9-G4 (5F9) is a first-in-class humanized antibody targeting CD47, a protective "dont eat me" signal on cancers, that stimulates tumor cell phagocytosis and an anti-tumor T cell response. Pre-clinically, 5F9 eliminates leukemic disease and induces durable remissions in patient-derived xenograft mouse models. This trial is the first to investigate an anti-CD47 antibody in AML patients. Aims The main objectives were to determine the safety, tolerability and recommended Phase 2 dose of 5F9 in *r/r* AML. Methods This Phase 1 trial enrolled *r/r* AML patients in a 3 3 dose escalation design (NCT02678338). An intra-patient dose escalation design was used with escalation

www.1stoncology.com/drug-pipeline-update/array2.php Safety, preliminary efficacy, PF232

Combination Therapy Analysis of Clinical Trials

Sub-Chapters:

- [Drug Status](#)
- [Pipeline Stages](#)
- [Development Timeline](#)
- [Compound Types](#)
- [Targets](#)
- [Pursued Tumor Types](#)
- [Clinical Results](#)
- [Clinical Biomarkers](#)
- [Combination Therapy](#)
- [Immuno-Oncology Pipeline](#)
- [Orphan and Breakthrough Drugs](#)
- [Selected Abstracts](#)
- [Originators/Owners](#)
- [Licensors/Collaborators](#)
- [BD&L Contacts](#)
- [Drug Profiles](#)

Combination Therapy

[Overview](#)
[All Combinations, Indications and Stages](#)
[Clinical Results from Combination Trials](#)

Show

Export Table Data:

Search:

entries

Drugs	Combination	Targets	Developmental Stage	Indications	Clinical Trial
<input type="text" value="Search Drugs"/>	<input type="text" value="Search Comb"/>	<input type="text" value="Search"/>	<input type="text" value="Search Develop"/>	<input type="text" value="Search Indications"/>	<input type="text" value="Search Clini"/>
Hu5F9-G4 [Forty Seven] - Phase II	Hu5F9-G4 + cetuximab	CD47 ▼ ▲	Phase II Clinical Trial	Cancer, breast Cancer, colorectal Cancer, head and neck Cancer, ovarian Cancer, pancreatic Cancer, solid, general	NCT02953782
Hu5F9-G4 [Forty Seven] - Phase II	Hu5F9-G4 + rituximab	CD47 ▼ ▲	Phase II Clinical Trial	Cancer, lymphoma, non-Hodgkin's Cancer, lymphoma, follicular Cancer, lymphoma, large b-cell, diffuse Cancer, lymphoma, B-cell, marginal zone	NCT02953509
ALX148 [ALX Oncology] - Phase I atezolizumab [Hoffmann-La Roche] - Marketed pembrolizumab [Merck & Co] - Marketed	ALX148 ± pembrolizumab / atezolizumab / trastuzumab	CD274 ▼ ▲ CD47 ▼ ▲ PDCD1 ▼ ▲	Phase I Clinical Trial	Cancer, lymphoma, general Cancer, lymphoma, non-Hodgkin's Cancer, solid, general	NCT03013218

Enhanced Company Profiles for Head-to-Head Pipeline Comparison and Analysis & More

Company Report: **Gilead Sciences**


[↑ Overview](#)
[✉ BD&L Contacts](#)
[↗ Internal Pipeline](#)
[↗ External Pipeline](#)

Internal Pipeline: 41 Drugs

Analyze By:

32 Targets

- [🔄 Drug Status](#)
- [🔄 Pipeline Stages](#)
- [🔄 Development Timeline](#)
- [🔄 Compound Types](#)
- [🔄 Targets](#)
- [🔄 Pursued Tumor Types](#)
- [🔄 Clinical Results](#)
- [🔄 Clinical Biomarkers](#)
- [🔄 Combination Therapy](#)
- [🔄 Immuno-Oncology Pipeline](#)
- [🔄 Orphan and Breakthrough Drugs](#)
- [🔄 Sales Figures](#)
- [🔄 Selected Abstracts](#)
- [🔄 Originators/Owners](#)
- [🔄 Licensors/Collaborators](#)
- [🔄 BD&L Contacts](#)
- [🔄 List of Drugs](#)



What's DRIVING ESMO?



- ❖ [Order Your Single User Access to “Commercial Interest at ESMO Annual Meeting 2018” Here](#)
- ❖ [Order Your Enterprise Access to “Commercial Interest at ESMO Annual Meeting 2018” Here](#)